The biotech company's shares plummeted in 2025. The post Could CSL shares reach $300 in 2026? appeared first on The Motley ...

Despite the difficult trading environment, leading brokers such as UBS maintain a positive outlook for CSL. They project that by FY26, CSL could achieve a net profit of US$3.46 billion, with earnings ...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any portfolio, there are likely to be some stocks that fall short of that benchmark.

This ASX heavyweight has potential to deliver superior returns but is more volatile. The post Is CSL or Sonic Healthcare the ...

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.